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There is increasing interest in the joint analysis of multiple phenotypes in genome-wide association studies (GWASs), especially for the
analysis of multiple secondary phenotypes in case-control studies and in detecting pleiotropic effects. Multiple phenotypes often mea-
sure the same underlying trait. By taking advantage of similarity across phenotypes, one could potentially gain statistical power in as-
sociation analysis. Because continuous phenotypes are likely to be measured on different scales, we propose a scaled marginal model for
testing and estimating the common effect of single-nucleotide polymorphism (SNP) on multiple secondary phenotypes in case-control
studies. This approach improves power in comparison to individual phenotype analysis and traditional multivariate analysis when phe-
notypes are positively correlated and measure an underlying trait in the same direction (after transformation) by borrowing strength
across outcomes with a one degree of freedom (1-DF) test and jointly estimating outcome-specific scales along with the SNP and covar-
iate effects. To account for case-control ascertainment bias for the analysis of multiple secondary phenotypes, we propose weighted esti-
mating equations for fitting scaledmarginalmodels. This weighted estimating equation approach is robust to departures from normality
of continuous multiple phenotypes and the misspecification of within-individual correlation among multiple phenotypes. Statistical
power improves when the within-individual correlation is correctly specified. We perform simulation studies to show the proposed
1-DF common effect test outperforms several alternative methods. We apply the proposed method to investigate SNP associations
with smoking behaviormeasured withmultiple secondary smoking phenotypes in a lung cancer case-control GWAS and identify several
SNPs of biological interest.Introduction
Genome-wide association studies (GWASs) have become a
popular approach for identifying common genetic variants
that are associated with disease phenotypes and quantita-
tive traits. Hundreds of GWASs have been conducted in
the last few years and have identified over 1,000 disease-
and trait-associated common single-nucleotide polymor-
phisms (SNPs).1 Many existing GWASs use a case-control
design, in which hundreds of thousands of SNPs are geno-
typed in a large number of disease-affected and disease-free
individuals in order to identify SNPs that are susceptible to
diseases.2,3,4 There is substantial interest in leveraging
these existing large case-control GWASs in order to identify
common variants associated with multiple secondary phe-
notypes that are often collected in these case-control
GWASs. For example, in the lung cancer (MIM 211980)
GWAS conducted at Massachusetts General Hospital
(MGH), four continuous traits measuring smoking
behavior were collected for both affected and control indi-
viduals, including the age of smoking initiation, smoking
duration, average number of cigarettes per day (CPD),
and number of years of smoking cessation. It is of interest
to conduct a GWAS analysis for the identification of SNPs
that are associated with smoking behavior by jointly
analyzing four smoking phenotypes while accounting for
case-control ascertainment bias.
Numerous GWAS analyses have been performed for
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analysis of continuous traits in cross-sectional and cohort
studies is to fit a linear regression model for each trait sepa-
rately. Because of the large number of SNPs analyzed,
GWAS analysis is plagued with a substantial multiple-
testing burden, making it challenging for SNPs to reach
genome-wide significance levels (e.g., p values < 107).
Furthermore, given that common variants often have
weak effects, as observed in many GWASs of complex
traits,1 many top SNPs identified in a GWAS are false posi-
tives.
Consequently, it is of substantial interest to develop
testing strategies to improve power in identifying SNPs
with weak effects in GWASs. Because multiple secondary
traits are likely to be correlated and to measure the same
underlying trait in different dimensions, joint analysis of
these traits by taking into account their correlation is likely
to improve power in comparison to individual trait anal-
ysis. In particular, joint analysis of multiple phenotypes
can borrow information across correlated multiple pheno-
types and increase effective sample sizes.8 Such joint
phenotype analysis also allows for the study of pleiotropic
effects.
However, when analyzing secondary phenotypes with
case-control designs, one needs to be mindful of ascertain-
ment bias. As described inMonsees et al.,9 in the context of
a single secondary phenotype, the bias is generally small
for analyses that ignore ascertainment or stratify on case-
control status, provided the marker is independent of2Department of Biostatistics, Harvard School of Public Health, Boston, MA
ard School of Public Health, Boston, MA 02115, USA
y, MD 21771, USA
.edu (X.L.)
y of Human Genetics. All rights reserved.
013
disease risk. Additional care must be taken when there is
evidence that both the secondary trait and the tested ge-
netic marker are associated with the primary disease. For
example, in the smoking GWAS analysis conducted in
this paper with lung cancer case-control samples, it is likely
that the same SNPsmight be associated with both smoking
and lung cancer.10,11 In this situation, naive analysis
ignoring case-control sampling is likely to result in bias
in the association analysis of smoking behavior. Monsees
et al.9 showed that inverse probability weighted (IPW)
regression for a single continuous outcome provides unbi-
ased estimates of marker-secondary trait association. Lin
and Zeng12 developed a retrospective likelihood method
for analyzing a single secondary phenotype in case-control
association studies. However, to date, the joint analysis of
multiple secondary phenotypes in case-control designs has
not been explored.
For cross-sectional and cohort studies, multivariate
regression methods, such as multivariate ANOVA13 and
generalized estimating equations,8 provide valuable tools
for analyzing multiple-phenotype data. These models
often use multiple degree of freedom (M-DF) tests to assess
the effects of an independent variable on multiple pheno-
types while accounting for the correlation between pheno-
types within the same individual. When multiple
phenotypes measure the same underlying trait in the
same direction (after transformation), power can be
improved by testing the shared or common effect of an in-
dependent variable on multiple phenotypes. Specifically,
in view of the fact that positively correlated continuous
phenotypes are often measured on different scales, Roy
et al.14 proposed a scaled marginal model for testing and
estimating the shared common effect of an independent
variable on multiple phenotypes in cross-sectional and
cohort studies, where a one degree of freedom (1-DF) test
was developed on the basis of estimating equations.
In this paper, we extend the work of Roy et al.14 and pro-
pose a scaled marginal model for genome-wide association
analysis of multiple continuous secondary phenotypes in
case-control studies. Specifically, when multiple pheno-
types are positively correlated and measure the same un-
derlying trait in the same direction (after transformation),
we propose the use of IPW-estimating equations in order to
estimate and test the shared common effect of SNPs on
multiple continuous secondary phenotypes in case-con-
trol studies. This approach accounts for case-control ascer-
tainment in analysis of secondary phenotypes with the use
of disease-prevalence-based inverse probability weights.
We term the proposed test the scaled multiple-phenotype
association test (SMAT). By jointly estimating outcome-
specific scale parameters with scaled marginal models,
the proposed SMAT method tests for the common effect
of SNP with a 1-DF test while allowing for phenotype-spe-
cific covariate effects. As an estimating-equation-based
approach, it accounts for arbitrary correlation among
multiple phenotypes and is robust to departure from
normality and misspecification of correlation amongThe Ammultiple continuous phenotypes. Furthermore, the
assumption of common effect can be tested with an esti-
mating-equation-based score test by comparing scaled
marginal models with heterogeneous SNP effect models.
Our simulation studies show that, when multiple phe-
notypes (after transformation) are positively correlated
and measure the same underlying trait or disease process
in the same direction, and if the scaled effects of multiple
phenotypes are homogeneous or moderately heteroge-
neous, the proposed 1-DF test SMAT for the common effect
of SNPs on multiple correlated phenotypes is more power-
ful than either testing the outcomes separately or testing
the outcomes jointly with the traditional M-DF test. In
addition, type I error is preserved in the presence of not
only case-control sampling but also heterogeneous SNP
effects that depart from the scaled marginal model with
common effect. We apply the proposed method to joint
analysis of the four smoking phenotypes in the MGH
lung cancer GWAS, which leads to the identification of
several top SNPs of biological interest.Material and Methods
The goal of the proposed method is to estimate and test for a com-
mon effect of SNP on the multiple secondary continuous pheno-
types in case-control designs when the multiple phenotypes
measure the same underlying trait in the same direction. First,
we describe the scaled marginal model14 below, and then we pro-
pose IPW-estimating equations for fitting the scaled marginal
model for multiple secondary continuous phenotypes to account
for case-control sampling.Scaled Marginal Model
Suppose that M correlated continuous phenotypes
yi ¼ ðyi1;.; yiMÞT , a SNP genotypic value si, and a vector of cova-
riates, xi ðp31Þ, are observed for the ith of n individuals. Typically,
we assume an additive genetic model where si represents the num-
ber of copies (or dosages for imputed data) of the minor allele.
Given that correlation among phenotypes within the same indi-
vidual is often unknown, a standard approach is to specify the
marginal means of the phenotype as
E

yij jxi; si
 ¼ xTi bj þ siaj ; j ¼ 1;.;M; (Equation 1)
where bj ðp31Þ are the covariate effects and aj is the SNP effect
corresponding to phenotype j. This model assumes the SNP si
has heterogeneous effects on the M phenotypes.
Estimation of regression coefficients can proceed with the use of
standard generalized estimating equations (GEE)15 and standard
software packages (e.g., the geeglm function in R Package gee-
pack16). To test for the hypothesis of no SNP effect on the M phe-
notypes, we can test the null hypothesis H0 : a

1 ¼. ¼ aM ¼ 0
with an M-DF test based on the Wald-type chi-square test statistic,
as described in Hjsgaard et al.16 and implemented in geepack. We
refer to this test as the traditional M-DF GEE test.
When multiple phenotypes are positively correlated and
measure the same underlying trait, more powerful tests can be
developed for testing the common effect of a SNP on multiple
phenotypes; e.g., the 1-DF test of the scaled marginal model.14erican Journal of Human Genetics 92, 744–759, May 2, 2013 745
Specifically, different phenotypes are often measured on different
scales. Denote by varðyijjxi; siÞ ¼ s2j the phenotype-specific vari-
ance conditional on covariates x and a SNP s. The scaled mar-
ginal model14 assumes that the SNP has a shared common effect
on the means of the scaled phenotypes,
E

yij jxi; si

sj
¼ xTi bj þ sia; j ¼ 1;.;M; (Equation 2)
where bj ðp31Þ are the covariate effects corresponding to pheno-
type j and a is the common shared effect of the SNP. There are
several notable features of Equation 2. First, the parameter a has
an attractive practical interpretation; that is, it is the common
effect size of SNP s on the M phenotypes. By using the scaling
parameter, this model alleviates the problem of differentially
scaled phenotypes that are often encountered in multiple-pheno-
type analysis. Second, the model allows for the common effect of
the SNP to be tested with a 1-DF test for H0 : a ¼ 0. Indeed, under
the common effect assumption, as shown in the simulation study,
this 1-DF test is more powerful than the M-DF GEE test.
One can examine the common effect assumption by consid-
ering the following scaled marginal model with heterogeneous
SNP effects:
E

yij jxi; si

sj
¼ xTi bj þ siaj; j ¼ 1;.;M; (Equation 3)
where aj is the (scaled) phenotype-specific SNP effect correspond-
ing to phenotype j. One can easily see the scaled heterogeneous
SNP effect model (Equation 3) reduces to the scaled common
effect model (Equation 2) when H0 : a1 ¼. ¼ aM ¼ a. Conve-
niently, Roy et al.14 provided a score-type test evaluating this hy-
pothesis for cross-sectional and cohort data.
Both Equation 2 and 3 specify only the meanmodels for pheno-
types and make no assumptions on the distribution of yij or the
correlation among the phenotypes. As shown in the following sec-
tions, our proposed estimation and testing procedures are, hence,
robust to misspecification of the correlation between phenotypes
within the same individual but are more powerful if the within-
individual correlation is correctly specified.Testing for Multiple Secondary Continuous
Phenotypes
In this section, we consider testing for a common effect of SNP on
multiple secondary continuous phenotypes in case-control
studies. First, for notational simplicity, we rewrite Equation 2 in
a matrix form,
Eðyi jXiÞ ¼ Xig; (Equation 4)
where yi ¼ ðyi1=s1;.; yiM=sMÞT ;
Xi ¼
8><>:
xTi 0
T . 0T si
0T xTi . 0
T si
« 1 «
0T 0T . xTi si
9>=>;
is an ðM3ðMpþ 1ÞÞ matrix, 0T is a p length row vector of zeros,
and g ¼ ðbT1 ;.;bTM ;aÞT .
Because affected individuals are oversampled in case-control
studies, analyzing multiple secondary continuous phenotypes
on the basis of the estimating equation methods of Roy et al.14
will yield biased results under the scaled common effect model746 The American Journal of Human Genetics 92, 744–759, May 2, 2(Equation 2). We correct for case-control biased sampling by using
weighted estimating equations,
Xn
i¼1
wiX
T
i R
1ðyi XigÞ ¼ 0 (Equation 5)
and
Xn
i¼1
wi

yij
sj

yij
sj
 xTi bj  sia

 1

¼ 0; j ¼ 1;.;M;
(Equation 6)
to jointly estimate the model parameters, where R ¼ RðqÞ is a
working correlation matrix dependent on parameter vector q, n
represents the sum of the total number of control individuals
ðn0Þ and total number of affected individuals ðn1Þ sampled (that
is, n ¼ n0 þ n1), and weight wi is proportional to the inverse prob-
ability that individual i was sampled in the study data set (see
Appendix A). The working correlation matrix, R, is used to
account for the correlation among multiple phenotypes and is
allowed to be misspecified.
When wi ¼ 1 for all i, the unweighted estimating equations
reduce to those in Roy et al.14, who showed that the estimation
of g and s2 (M 3 1) are unbiased for an arbitrary working correla-
tion matrix, R, for cross-sectional and cohort studies. To account
for case-control ascertainment, theweights are a functionofdisease
prevalence, which is assumed to be known or estimated with
external information. Specifically, theweightwi is specified toeffec-
tively upweight the control individuals and downweight the
affected individualswhen the disease in the population is rare, as in
wi ¼
8>><>>:
p
pn
if Di ¼ 1
1 p
1 pn if Di ¼ 0
(Equation 7)
wherep is the disease prevalence in the population,Di is an indica-
tor of an affected or control (1/0) individual, and pn ¼ n1=n is the
proportion of affected individuals in the case-control sample.17
In Appendix A, we show that that the weighted estimating equa-
tions (Equations 5 and 6) are unbiased for an arbitrary working
correlation matrix R. A more efficient estimator of g, that is, the
estimator with a smaller variance, might be obtained when the
working correlation R is correctly specified as the true correlation
among the multiple secondary phenotypes yij. Note that, for
simplicity, the within-individual correlation is not accounted for
in the estimation of s2j in Equation 6, given that the s
2
j are nuisance
parameters and their estimation uses more complex quadratic esti-
mating equations. More importantly, the efficiency of the regres-
sion coefficient estimator of g only requires a consistent estimator
of the scale parameter s2j , which is provided by the simple working
independence estimators of the s2j given in Equation 6.
Estimation can proceed with the use of a modified Gauss-Seidel
algorithm that alternates between the estimation of g and s2 until
convergence. The standard errors of the estimates are provided
with the sandwich method. Details for parameter and standard
error estimation are provided in Appendix B.
The common effect of the SNP s on theM secondary continuous
phenotypes can be tested for the null hypothesis H0 : a ¼ 0 with
the use of a 1-DF test, Z ¼ ba=cSEðbaÞ, where cSEðbaÞ is the sandwich
estimate for the standard error given in Appendix B. We term
this 1-DF scaled common effect test as the SMAT. Implementation
is very fast and available in the R package SMAT.
It should be noted that the 1-DF SMAT developed under the
scaled common effect model (Equation 2) for the SNP effect on013
the M secondary continuous phenotypes is still valid when the
scaled SNP effects are in fact heterogeneous. In other words, sup-
pose the data follow the scaled heterogeneous SNP effect model
(Equation 3); then, under the null hypothesis of no association be-
tween the SNP s and theM secondary continuous phenotypes, the
type I error rate of the 1-DF Z test is still preserved, although it
might lose power if the degree of heterogeneity of scaled SNP ef-
fects between different phenotypes is large. However, because
common variants often have weak effects in GWASs, the degree
of heterogeneity of scaled SNP effects between different pheno-
types is usually low. As shown in our simulation studies, in prac-
tice, when multiple phenotypes are positively correlated and
measure the same underlying trait in the same direction (after
transformation), the simple 1-DF SMAT has more power than
the traditional M-DF GEE test that allows a SNP to have different
effects on different phenotypes, even when the heterogeneous
SNP effect model (Equation 3) is used to generate the data.
Test for the Assumption of Scaled Common Effect
One can construct similarly weighted estimating equations under
the heterogeneous SNP effect model (Equation 3) by simply modi-
fying Xi and g in Equation 5 and replacing xTi bþ sia with
xTi bþ siaj for phenotype yij in Equation 6, and one can jointly
estimate the model parameters by solving these equations.
Consideration of this model allows one to test easily for the appro-
priateness of the scaled common effect assumption.
Specifically, under the heterogeneous scaled SNP effect model
(Equation 3), the null hypothesis for a scaled common effect for
SNP is H0 : a1 ¼. ¼ aM . This null hypothesis can be equivalently
written as
E

yij jxi; si

sj
¼ xTi bj þ sih1 þ siIðj > 1Þhj; (Equation 8)
where h1 ¼ a1 is set as the baseline and hj ¼ aj  a1; jR2. The
equivalent null hypothesis of homogeneity becomes
H0 : h2 ¼. ¼ hM ¼ 0, which corresponds to the scaled common
effect model (Equation 2). One can test for this null hypothesis
with the use of the estimating-equation-based score test.14 Because
the score test is constructed under the null hypothesis, the test
only relies on the fit under the scaled common effect model (Equa-
tion 2). Conveniently, this scaled common effect model is the
same model used to compute the 1-DF SMAT described in Testing
for Multiple Secondary Continuous Phenotypes.
Note that the 1-DF SMAT is still valid in the sense of a protected
type I error rate, even under SNP effect heterogeneity. In practice,
we can run the 1-DF SMAT and the homogeneity test simulta-
neously for each SNP and then evaluate the appropriateness of
the homogeneity (common effect) assumption post hoc. Details
of the homogeneity test formultiple secondary continuous pheno-
types in case-control samples can be found in Appendix C. Under
the null hypothesis of homogeneity or common effect, the score
statistic asymptotically follows a c2 distributionwithM  1 degrees
of freedom. In the R Package SMAT, the score statistic and its associ-
atedpvalueare alsomadeavailable to theuser. Thesimulationstudy
shows that the 1-DF SMAT is often more powerful than the M-DF
GEE test, evenwhen theheterogeneous effectmodel is true if the ef-
fects of a SNP on multiple phenotypes are in the same direction.
Simulation: Empirical Performance of SMAT
We performed simulation studies to compare the joint analysis of
the multiple outcomes using the 1-DF scaled common effect testThe Am(SMAT) with two alternative types of joint outcome tests: (1) the
minimum adjusted p value analysis based on single-outcome tests
adjusting for multiple comparisons (to be described in more detail
in Control-Only Simulation) and (2) the standard M-DF multivar-
iate GEE analysis based on the unscaled model allowing outcome-
specific SNP effects (that is, the M-DF GEE test resulting from
Equation 1). First, we considered a set of simulations in which
all M outcomes are associated with SNP, where we generated
data to roughly mimic the actual smoking behavior GWAS data
for SNPs within CDH18 (MIM 603019) on chromosome 5. This
gene was selected because five of the top ten SNPs identified in
the actual data analyses are located within this gene (see GWAS
on Smoking Behavior and Table 4). More specifically, for each
simulated data set, we randomly selected a single SNP from the
88 typed CDH18 SNPs to be the ‘‘causal’’ SNP, and we considered
M ¼ 4 outcomes, with covariates age, gender (0 ¼ male,1 ¼
female), and education (college education or more; 0 ¼ no,1 ¼
yes). For comparison, we used the function geeglm from R package
geepack16 to perform (unscaled) single-outcome-based minimum
adjusted p value analysis and multivariate M-DF-based GEE anal-
ysis with the Wald-like sandwich standard error estimates. For
both multivariate methods, we considered three working correla-
tion structures among the outcomes: independent, exchangeable,
and unstructured. The second set of simulations examines the sit-
uation in which not all outcomes are associated with SNP.
We provide details of the first set of simulations below, where
the control-only and control þ affected simulations are described
in turn. In both scenarios, we examined empirical size and power
in two data-generation model types: a ‘‘scaled common effect
model,’’ where the data are generated under the scaled homoge-
neous effect assumption (that is, under Equation 2;
a ¼ aj; j ¼ 1;.;M), and a ‘‘scaled heterogeneous effect model,’’
where the scaled homogeneous (common) effect assumption
does not hold (that is, under Equation 3; asaj; j ¼ 1;.;M).
Power is estimated as a function of SNP effect size, which corre-
sponds to a in the scaled common effect model or the average
aA ¼ M1
P
jaj in the scaled heterogeneous effect model. In all
settings for a given a ðaAÞ, each simulated data set was generated
by sampling n0 ¼ 700 covariate-SNP ðfxi; sigÞ pairs from the
MGH control group and then sampling n1 ¼ 700 covariate-SNP
ðfxi; sigÞ pairs from the MGH affected group (if necessary). Note
that n0 ¼ n1 ¼ 700 was selected in order to mimic the actual sam-
ple sizes used in analysis in GWAS on Smoking Behavior. Using
these values, we generated M ¼ 4 outcomes ðyij; j ¼ 1;.;4Þ ac-
cording to a multivariate normal model with parameters as spec-
ified in Table 1 (based on estimates from the MGH data) and the
given a ðaAÞ, so that yij=sj has a mean of xTi bj þ sia in the scaled
common effect model and a mean of xTi bj þ siaj in the scaled het-
erogeneous effect model; parameter specifications for a and aj;
j ¼ 1;.;4 are discussed in more detail in Control-Only Simula-
tion and Control þ Affected Simulation below. For each data-gen-
eration model type, we also considered two true correlation
structures, exchangeable and unstructured, with values specified
in Table 1 based on the actual MGH data. In the interest of space,
only results which use the unstructured correlation matrix are
reported.
Control-Only Simulation
To investigate empirical size, we generated B ¼ 107 data sets as
described above with a ¼ aj ¼ 0; j ¼ 1;.;4; that is, no SNP effect.
For each data set, we computed p values from the 1-DF SMAT,
4-DF GEE test, and the single-outcome-based minimum adjustederican Journal of Human Genetics 92, 744–759, May 2, 2013 747
Table 1. Simulation Parameters
Parameters:
b1 ¼ ð2:0;0:1;0:1;0:5ÞT Rð0Þ ¼ Rð1Þ (U):
b2 ¼ ð8:0;0:1;0:5;0:5ÞT 0BBBBBB@
1:0 0:2 0:3 0:5
0:2 1:0 0:3 0:1
0:3 0:3 1:0 0:1
0:5 0:1 0:1 1:0
1CCCCCCA
b3 ¼ ð3:5;0:0;0:5;0:3ÞT
b4 ¼ ð1:0;0:1;0:2;0:4ÞT
s2ð0Þ ¼ ð2:0;0:5;2:5;4:0ÞT
s2ð1Þ ¼ ð1:5;0:5;2:0;4:0ÞT Rð0Þ ¼ Rð1Þ (E): r ¼ 0:25
We set aR0; simulated yi were designed to correspond to actual data
yi ¼ ð
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
DURATION
p
;
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
INITIATION
p
; ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCPDp ; ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCESSATIONp ÞT ; the covariate
effects bj correspond to intercept, age (continuous), gender (0 ¼ M, 1 ¼ F),
and college education (college graduate 0 ¼ no, 1 ¼ yes).p value test. Note that weighting is not necessary here because we
are only considering the control samples which, under a rare dis-
ease assumption, will approximate a random sample from the
population. Thus, all tests were implemented with wi ¼ 1 for all
i ¼ 1;.;n0. Size for the SMAT and GEE tests were defined as the
proportion of p values less than or equal to a specified threshold
(e.g., 0.01, 0.001, etc.). For the joint outcome analysis with the sin-
gle-outcome-based minimum adjusted p value tests, we analyzed
each outcome separately and calculated the adjusted p values, ac-
counting for multiple and correlated tests across the M ¼ 4 out-
comes with the method of Conneely and Boehnke18. Then, we
defined the associated ‘‘joint’’ analysis p value as the minimum
of the individual adjusted p values across the M ¼ 4 outcomes
and similarly characterized size for this ‘‘min-adj p’’ testing proce-
dure as the proportion of minimum adjusted p values less than or
equal to a specified threshold.
Under the scaled common effect data-generation model, we
examined power as a function of SNP effect size, a, whereas, under
the scaled heterogeneous data-generation model, we examined
power as a function of the average, aA:On the basis of the analysis
of SNP rs4242066 from CDH18 in the MGH data (Table 4) with re-
sulting estimator baz0:3, we specified a in simulation to be 0:3  c
for a range of c: Similarly, to generate heterogeneous effects, we
considered ð0:35;0:25;0:325;0:40ÞT  c; (e.g., aAz0:3 for c ¼ 1)
for the same range of c, where the parameter values were obtained
from the analysis of the MGH data. Note that the assumption of
scaled common effect for SNP in the sense of that given in Test
for the Assumption of Scaled Common Effect does not hold for
such a specification of aj; j ¼ 1;.;4: For each configuration, we
performed 1,000 runs. For each simulated data set, we calculated
the p values using the 1-DF SMAT, 4-DF GEE, and the min-adj p
test. Then, we calculated power by computing the proportion of
times across all simulated data sets that the p values were less
than or equal to 105. Note that the use of the threshold 105 is
merely for illustration, given that the resulting power curves dis-
cussed in the Results have similar patterns for other significance
levels as well (data not shown).Control þ Affected Simulation
As before, to investigate empirical size, we generated B ¼ 107 data
sets under the null hypothesis of no SNP effect and computed for
each data set p values from the 1-DF SMAT and 4-DF GEE test, as
well as the minimum adjusted p values from the single-outcome
tests (that is, min-adj p test). In order to account for potential748 The American Journal of Human Genetics 92, 744–759, May 2, 2ascertainment bias, all testing procedures required weighting; in
particular, the weighted estimating equations (Equations 5 and
6) were used for the computation of SMAT.We considered two dis-
ease prevalences, low ðp ¼ 0:000745Þ and moderate ðp ¼ 0:0745Þ,
and used the corresponding prevalence to define the weight. Size
was defined in the same manner as in the control-only analysis.
Additionally, for power, we considered situations in which the
SNP effect for the affected individuals was the same or different
from that for the control individuals. The latter situation amounts
to fitting a misspecified model, because this scenario implies a dis-
ease-dependent SNP effect. In situations in which SNP effect was
generated as the same value in both affected and control individ-
uals (disease-independent), power was evaluated as described in
the control-only analysis; that is, as a function of a and aA for
the scaled common and scaled heterogeneous data-generating
models, respectively. However, when simulating under different
SNP effect parameters for the affected and control individuals (dis-
ease-dependent), a new metric of effect size is needed to evaluate
power. In particular, we assumed the following population models
for common effect for the diseased ðDi ¼ 1Þ and nondiseased
ðDi ¼ 0Þ individuals, respectively, for j ¼ 1;.;M ¼ 4 outcomes:
E

yij jxi; si;Di ¼ 1

sj
¼ xTi bð1Þj þ siað1Þ (Equation 9)
E

yij jxi; si;Di ¼ 0

sj
¼ xTi bð0Þj þ siað0Þ: (Equation 10)
With disease prevalence p; the population mean is
E

yij jxi; si

sj
¼ E
(
E

yij jxi; si;Di

sj
)
¼ xTi bpj þ siap; (Equation 11)
where bpj ¼ pbð1Þj þ ð1 pÞbð0Þj is the population covariate effect,
and ap :¼ pað1Þ þ ð1 pÞað0Þ is the population SNP effect pooled
over disease-affected and control individuals. In this scenario,
we considered power as a function of ap, where a
ð0Þ ¼ 0:3c for
the control individuals and að1Þ ¼ 0:01c for the affected individ-
uals over a range of c. This choice corresponds to a much stronger
effect in the control individuals and very little effect in the affected
individuals, as observed in some SNPs in the MGH data set.
For the scaled heterogeneous effect model, Equations 9 and 10
are modified such that að1Þ and að0Þ each have j subscripts; hetero-
geneous SNP effects for the control individuals were generated in
the same way as in the control-only analysis (e.g., a
ð0Þ
A z0:3 for
c ¼ 1), whereas heterogeneous SNP effects for the affected individ-
uals were varied according to ð0:002;0:001;0:003;0:200ÞT  c (e.g.,
a
ð1Þ
A z0:05 for c ¼ 1) for a range of c: Again, this choice corresponds
to a much stronger effect in the control individuals and very
little effect in the affected individuals but also incorporates
heterogeneity in the SNP effects in both affected and control
individuals. Here, power is considered as a function of
aAp :¼ pað1ÞA þ ð1 pÞað0ÞA for comparison.Subset of Phenotypes Associated with SNP
The second set of simulations examines the performance of SMAT
under the situation where not all outcomes are associated with
SNP. Let M0 denote the number of outcomes associated with
SNP or, equivalently, the number of ajs0; j ¼ 1;.;M: For this
set of simulations, we consider M0˛f2;3;4g for M ¼ 4 outcomes
and also M0˛f5;8;10g for M ¼ 10 outcomes in both the control-
only and control þ affected scenarios (disease-independent013
only), and, for simplicity, specify the correlation between the
M0 phenotypes associated with SNP to be 0.25 and the corre-
lation between the M M0 phenotypes not associated with SNP
to also be 0.25. However, we specify the correlation between the
M0 ‘‘associated’’ phenotypes and M M0 ‘‘nonassociated’’ pheno-
types to be 0.05. Similar to the first set of simulations, we consider
the same scaled heterogeneous SNP effect vector,
ð0:35;0:25;0:325;0:40ÞT  c, for M ¼ M0 ¼ 4 over a range of c.
Note that this simulation for M0 ¼ M ¼ 4 is exactly the same
as the simulation described above when using a true
exchangeable correlation matrix to generate the multiple
phenotypes. When M0 < M ¼ 4, we set the last M M0 scaled
SNP effects aj to 0. All of the remaining simulation parameters
(e.g., covariate regression coefficients and phenotype-specific
scales) were specified according to Table 1. For M0 ¼ M ¼ 10; the
scaled heterogeneous SNP effect vector was set to
ð0:35;0:25;0:325;0:40;0:30;0:30;0:20;0:275;0:35;0:375ÞT  c for
a range of c; for M0 < M ¼ 10, we set the last M M0 effect
sizes to 0. Parameters bj, j ¼ 5;.;10 were set to be roughly
the same magnitude as those for bj,j ¼ 1;.;4 in Table 1, and we
set s2ð0Þ ¼ ð2:0;0:5;2:5;4:0;0:75;1:25;2:0;1:75;2:25;1:0ÞT and
s2ð1Þ ¼ ð1:5;0:5;2:0;4:0;0:75;1:25;2:0;1:75;2:25;1:0ÞT : As before,
we evaluate power as a function of average scaled effect size,
aA ¼ M1
PM
j¼1aj. Note that, when M0 is considerably smaller
than M (that is, there are a substantial number of null pheno-
types), the scaled common effect assumption that underlies
SMAT is considerably violated and can be detected by the scaled
homogeneity test examined in the next section; power loss of
SMAT is expected in this situation.Simulation: Empirical Performance of Test for Scaled
Homogeneity
Finally, we investigated the empirical size and power for the test of
scaled homogeneity, used to evaluate the scaled common effect
assumption, under the control-only and control þ affected set-
tings. As in the simulations described above for the 1-DF scaled
common effect test (SMAT), we generated data that roughly
mimicked the actual smoking behavior GWAS data for SNPs
within CDH18 on chromosome 5, where, for each simulated
data set, we randomly selected a single SNP from the 88 typed
CDH18 SNPs to be the ‘‘causal’’ SNP, and we consideredM ¼ 4 out-
comes with covariates for age, gender (0 ¼ male,1 ¼ female), and
education (college education or more; 0 ¼ no,1 ¼ yes). Again, we
generated the data using a multivariate normal model with simu-
lation parameters specified in Table 1, and the specification of the
SNP effects are described below. For the controlþ affected settings,
we considered the low and moderate disease-prevalence levels
ðp˛f0:0745;0:000745gÞ as well as disease-independent and dis-
ease-dependent SNP effects on the four phenotypes.
In the control-only and control þ affected/disease-independent
settings, we examined empirical size by generating B ¼ 5000 data
sets under the null hypothesis, each with a ¼ aj ¼ 0:3 (homogene-
ity or common effect), j ¼ 1;.;4, and performing the estimating
equation-based score test for H0 : a1 ¼. ¼ a4 as described in Test
for the Assumption of Scaled Common Effect (see also Appendix
C). Empirical size was estimated as the proportion of score test p
values less than or equal to 0.05. To complement the simulations
above for the 1-DF SMAT, we also considered the disease-depen-
dent setting, where að0Þ ¼ að0Þj ¼ 0:3 and að1Þ ¼ að1Þj ¼ 0:05; for
j ¼ 1;.;4: As above, this corresponds to a common population
SNP effect, ap, pooled over disease-affected individuals and controlThe Amindividuals. Empirical size in this setting was also estimated as the
proportion of score test p values less than or equal to 0.05.
We examined power as a function of SNP heterogeneity for a
fixed (scaled) average SNP effect across outcomes; that is, fixed
aA ¼ 0:3 for the control-only and control þ affected (disease-inde-
pendent) settings and fixed aAp ¼ 0:05pþ 0:30ð1 pÞ for the
control þ affected (disease-dependent) setting. The degree of het-
erogeneity was controlled by varying the parameter k in the equa-
tions aj ¼ aA5k  d for j ¼ 1;2 and aj ¼ aA5k  d=2 for j ¼ 3;4;
where d is a fixed SD of the scaled SNP effects. For example, in
the control-only and control þ affected (disease-independent)
simulations, we set k˛f0;0:5;1;1:5;.;3;3:5g with d ¼ 0:0625,
where d was estimated from the observed MGH smoking data.
These selections correspond to SDs of aj for j ¼ 1;.;4 in the range
of 0 to 0.20. Heterogeneous SNP effects a
ð0Þ
j and a
ð1Þ
j for j ¼ 1;.;4
were defined analogously for the disease-dependent simulations
with the same range of k with a
ð0Þ
A ¼ 0:3; dð0Þ ¼ 0:0625 and
a
ð1Þ
A ¼ 0:05; dð1Þ ¼ 0:0125, where dð0Þ and dð1Þ were estimated
from the observed MGH smoking data. Defining apj ¼
pa
ð1Þ
j þ ð1 pÞað0Þj as the population SNP effect for outcome j;
pooled over disease-affected individuals and control individuals,
these parameter selections correspond to SDs of apj; for
j ¼ 1;.;4; between 0 and 0.20 for the low disease-prevalence level
and between 0 and 0.19 for the moderate disease-prevalence level.
These configurations allow us to vary the degrees of heterogeneity
of the population SNP effects across multiple phenotypes.GWAS on Smoking Behavior
To demonstrate the applicability and power of our approach, we
applied the 1-DF SMAT, 4-DF GEE, and min-adj p tests to SNPs
fromourmotivating lungcancerGWAS.Weexamined four second-
ary traits related to smoking behavior: age of initiation, smoking
duration (in years), average CPD, and years of smoking cessation.Study Population
From a large ongoing case-control study of the molecular epidemi-
ology of lung cancer at MGH, we derived a study population of
affected and control individuals. The controls, individuals with
no diagnosis of lung cancer, were recruited among friends or
spouses of the lung cancer affected individuals or friends or
spouses of other cancer or surgery patients in the same hospital.
Potential control individuals that experienced a previous diag-
nosis of any cancer (excluding nonmelanoma skin cancer) were
not eligible to participate. Proper informed consent was obtained
from all participants. To reduce confounding due to population
structure, the study was limited to individuals of self-reported Eu-
ropean descent. Demographic and smoking characteristics of the
ever-smoker (former and current smokers) study population of in-
terest are provided in Table 2. The study was reviewed and
approved by Institutional Review Boards of MGH and the Harvard
School of Public Health.Genotyping
Peripheral blood samples were obtained from participants at the
time of enrollment. DNA was extracted from samples with the
Puregene DNA Isolation Kit (Gentra Systems), and genotyping
was performed with the Illumina Human610-Quad BeadChip.
We excluded SNPs that had call rates less than 95%, that failed
Hardy-Weinberg equilibrium tests at 106, or that had minor
allele frequency (MAF) less than 5%. Samples with genotyping
call rates less than 95% were also excluded. There wereerican Journal of Human Genetics 92, 744–759, May 2, 2013 749
Table 2. Demographic Characteristics
Control Affected
Former (N ¼ 555) Current (N ¼ 254) Former (N ¼ 501) Current (N ¼ 391)
Age 61.69 (10.60) 53.66 (11.59) 68.94 (9.21) 61.44 (10.12)
Gender (M) 289 (52%) 91 (36%) 279 (56%) 197 (50.4%)
College Grad (Y) 175 (32%) 47 (19%) 134 (27%) 69 (18%)
Age of Smoking Initiation 17.06 (3.95) 17.00 (4.95) 17.32 (4.40) 16.56 (3.90)a
Smoking Duration 26.38 (14.47) 35.38 (11.76) 39.48 (14.09) 44.25 (10.33)a
Average CPD 21.07 (14.72) 20.67 (11.33) 28.98 (14.88) 27.98 (13.31)a
Years of Smoking Cessation 20.54 (11.92) 0.04 (0.16) 17.22 (11.84) 0.13 (0.22)b
Demographic Characteristics of the study participants in the MGH lung cancer study. Entries are mean (SD) for continuous variables and count (percentage) for
binary variables.
aN ¼ 389.
bN ¼ 384.513,271 SNPs remaining after frequency and quality control. To
detect and further control for population structure, we used
EIGENSTRAT (version 2.0) to perform a principal component
analysis.19 We used the first four principal components, on
the basis of significant ðp < 0:05Þ Tracy-Wisdom tests and
genomic control (GC) inflation factor, as covariates for all
analyses.
Covariate and Phenotypic Data Collection
Interviewer-administered questionnaires (a modified version of
the detailed American Thoracic Society health questionnaire)
collected demographic information and detailed smoking
histories from each individual. Some participants preferred to
complete the questionnaire at home and return it by mail in
a self-addressed stamped envelope. When data were incomplete
or missing, participants were contacted by telephone. The co-
variate age was defined as a continuous variable from date of
birth to the time of recruitment, and gender was coded as
male versus female. The covariate college education was defined
as having a college education or more (yes or no). Smoking sta-
tus was defined as never smoker (less than 100 cigarettes in
their lifetime), former smoker (quit smoking at least 1 year prior
to interview date), or current smoker (at time of interview).
Only ever-smokers were used in our analysis of smoking
behavior. Information on our four phenotypic measures of
smoking behavior (age of smoking initiation, smoking duration,
average CPD, and date of smoking cessation) was obtained
directly from the questionnaire. Note that n0 ¼ 730 control
and n1 ¼ 696 affected ever-smoker individuals have genotypic,
covariate, and phenotypic information. This subset was used
in all subsequent analyses.
Although normality is not required for our proposed estimating
equation approach, we used the square root transformation on all
of the continuous smoking phenotype variables to enable compar-
isons with single-outcome regression analyses relying on
normality. We performed the 1-DF SMAT on control-only as well
as the control þ affected individuals across the entire GWAS data
set to examine the common effect of each SNP on ‘‘less smoking,’’
as quantified by the four transformed outcomes (with the trans-
formed duration and CPD outcomes negated so the outcomes are
all positively correlated; that is,  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃDURATIONp , ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃINITIATIONp ,
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCPDp , and ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCESSATIONp ), adjusting for age, gender, college edu-
750 The American Journal of Human Genetics 92, 744–759, May 2, 2cation, and the four principal components to correct for popula-
tion substructure.Results
Simulation: SMAT
Control-Only Analysis
Size results for the control-only analysis are presented in
the first column of Table 3. On the basis of simulations
with n0 ¼ 700 individuals in each data set, all empirical
size estimates are approximately preserved. Interestingly
the 4-DF GEE test exhibits a slightly inflated type I error
rate, perhaps because of the instability of the sandwich
estimator. Note that increasing the sample size to
n0 ¼ 1400 results in more accurate size estimates, particu-
larly for the 4-DF GEE test (data not shown). Also note
that the size results for all three working correlation struc-
tures were considered (I, independent; E, exchangeable;
and U, unstructured) and were similar for the 4-DF GEE
test and the 1-DF SMAT.
We present the power results for both data-generation
models (both of which used the unstructured correlation
Rð0ÞðUÞ given in Table 1 to generate the data) in Figure 1.
Power is plotted as a function of a and aA, respectively,
for the scaled common and heterogeneous effect models.
Given that the 1-DF SMAT implicitly assumes a scaled com-
mon effect model, we see, as expected, more power gains
in the 1-DF SMAT over the 4-DF GEE test and the min-
adj p test in the correctly specified homogeneous genera-
tion model (Figure 1A) than in the scaled heterogeneous
generation model (Figure 1B). However, even with the
scaled heterogeneous data generation model, the 1-DF
SMAT still has higher power than both the 4-DF GEE test
and the single-outcome-based min-adj p test. In both situ-
ations, the 1-DF SMAT with an unstructured working cor-
relation matrix slightly outperforms the 1-DF SMAT with
the use of either the exchangeable or independent working
structures.013
Table 3. Empirical Size Results
Method Size Control-Only Control þ Affected (LOW)a Control þ Affected (MOD)a
min-adj p 102 1.32 3 102 1.32 3 102 1.31 3 102
103 1.70 3 103 1.71 3 103 1.68 3 103
104 2.58 3 104 2.61 3 104 2.47 3 104
105 4.15 3 105 4.14 3 105 3.77 3 105
(weighted) traditional GEE 102 1.62 3 102 1.63 3 102 1.60 3 102
(4-DF; I/E/U) 103 2.59 3 103 2.61 3 103 2.51 3 103
104 5.32 3 104 5.37 3 104 4.89 3 104
105 1.09 3 104 1.10 3 104 9.29 3 105
(weighted) SMAT 102 1.17 3 102 1.17 3 102 1.16 3 102
(1-DF; I/E) 103 1.41 3 103 1.41 3 103 1.42 3 103
104 1.89 3 104 1.90 3 104 1.94 3 104
105 2.89 3 105 2.89 3 105 2.71 3 105
(weighted) SMAT 102 1.19 3 102 1.19 3 102 1.16 3 102
(1-DF; U) 103 1.44 3 103 1.42 3 103 1.41 3 103
104 1.86 3 104 1.86 3 104 1.83 3 104
105 3.09 3 105 3.10 3 105 2.81 3 105
Empirical size results for B ¼ 107 simulated data sets and n0 ¼ n1 ¼ 700 assuming the true correlation among the phenotypes is unstructured, as given in Table 1.
For multiple phenotype analyses, independent (I), exchangeable (E), and unstructured (U) working correlation structures were considered. The results from the 4-
DF GEE test with I, E, and U working correlation structures are nearly identical. The results from the 1-DF SMAT with the I and E working correlation structures are
nearly identical.
aLOW and MOD refer to disease prevalence p ¼ 0:000745 and p ¼ 0:0745; respectively.Control þ Affected Analysis
The empirical size results for the control þ affected ana-
lyses are presented in the second and third columns of
Table 3 and are quantitatively very similar to those from
the control-only analyses, regardless of disease prevalence.
The empirical sizes are close to the nominal values. Like-
wise, increasing the sample size to n0 ¼ n1 ¼ 1400 results
in more accurate size estimates (data not shown).
We present the power results for the scaled common ef-
fect data generation models assuming unstructured corre-
lation (that is, generated with Rð0Þ ¼ Rð1ÞðUÞ in Table 1)The Amin Figure 2 for both the low (left column) and moderate
(right column) disease prevalences and same (disease-inde-
pendent; top row) and different (disease-dependent;
bottom row) SNP effects for the affected and control indi-
viduals. For each plot, we see again that the 1-DF SMAT
dominates in terms of power. Power is not sensitive to
the presence of disease-dependent SNP effects as a conse-
quence of the appropriate weighting.
Figure 3 displays the analogous plots for the scaled het-
erogeneous effect data generationmodel assumingunstruc-
tured correlation (that is, generated with Rð0Þ ¼ Rð1ÞðUÞFigure 1. Power for Control-Only Anal-
ysis
Power results for control-only analysis
ðn0 ¼ 700Þ from the (A) scaled common
(homogeneous) effect data-generation
model and (B) scaled heterogeneous effect
data-generation model. Although the data
were generated with an unstructured cor-
relation matrix, three working correlation
matrix structures for the joint outcome an-
alyses were considered: I, independent; E,
exchangeable; and U, unstructured. Power
results were nearly identical with the use
of I, E, and U for the 4-DF GEE tests,
whereas power results were nearly iden-
tical with I and E, but not U, in the 1-DF
SMAT; thus, only the results for GEE (U)
and SMAT (E and U) are included.
erican Journal of Human Genetics 92, 744–759, May 2, 2013 751
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Figure 2. Power for Control þ Affected
Analysis under the Scaled Common Effect
Model
Power results for control þ affected anal-
ysis ðn0 ¼ n1 ¼ 700Þ from the scaled com-
mon (homogeneous) effect data-genera-
tion model for both the low (left, A and
C) and moderate (right, B and D) disease
prevalences and same (top, A and B) and
different (bottom, C and D) SNP effects
for the affected and control individuals;
that is, columns compare power with
low ðp ¼ 0:000745Þ versus moderate
ðp ¼ 0:0745Þ disease prevalences, and,
thus, the effects of the weights, wi, and
rows compare power for disease-indepen-
dent ðað0Þ ¼ að1ÞÞ versus disease-dependent
ðað0Þsað1ÞÞ SNP effects. Although the data
were generatedwith an unstructured corre-
lation matrix, three working correlation
matrix structures for the joint outcome an-
alyses were considered: I, independent; E,
exchangeable; and U, unstructured. Power
results were nearly identical with the use of
I, E, and U for the 4-DF GEE tests, whereas
power results were nearly identical with I
and E, but not U, in the 1-DF SMAT; thus,
only the results for GEE (U) and SMAT (E
and U) are included.in Table 1). As in the control-only simulation results
(Figure 1B), the 1-DF SMAT still has higher power than
both the 4-DF GEE and min-adj p tests, even when the
scaled SNP effects are in fact heterogeneous. The gain in
power experienced here, as well as in the scenario with
true exchangeable correlation (that is, data generated
with Rð0Þ ¼ Rð1ÞðEÞ in Table 1) (data not shown), is due
largely to the reduced degrees of freedom and moderate
deviations from homogeneity under the scaled model.
Subset of Phenotypes Associated with SNP
We present the power results for the situation where a sub-
set of phenotypes is associated with SNP in Figure 4 for the
control-only analysis. The results for control þ affected
analysis are similar and are included in the Supplemental
Data (Figure S1). In these figures, the top (bottom) row dis-
plays the results for M ¼ 4 ðM ¼ 10Þ phenotypes for vary-
ing numbers of SNP-associated phenotypes,M0. For a fixed
sample size, we anticipated that the power of all tests
would depend on a combination of factors, including the
degree of correlation among phenotypes, the number of
nonzero aj (sparsity), and signal strength (magnitude) of
nonzero aj: For SMAT, the signal strength of nonzero aj
additionally influences heterogeneity among the scaled
SNP effects.
Our simulation results indicate that, when only 50% of
the phenotypes are associated with SNP, SMAT has less po-
wer, and the M-DF GEE test is recommended. Note that, in
this setting, the scaled common effect assumption under752 The American Journal of Human Genetics 92, 744–759, May 2, 2013SMAT is strongly violated. For
example, when M0 ¼ 2 and M ¼ 4,
we conducted additional simulationsto test for scaled homogeneity. For the last three power
points, where the discrepancy between the methods is
the greatest (aA near 0.10, 0.12, and 0.15), the sample me-
dian p values for the test of scaled homogeneity across
1,000 simulations are respectively 0.039, 0.005, and
0.0002, suggesting that the scaled homogeneity assump-
tion is not satisfied in well over 50% of the simulated
data sets at the 0.05 level.
When about 75% of the phenotypes are associated with
SNP, SMAT has similar power to the M-DF GEE test when
M ¼ 4 and has a higher power when M ¼ 10. In fact,
when M0 ¼ 3 and M ¼ 4, our additional simulations for
examining scaled homogeneity suggest for the last three
power points (aA near 0.15, 0.20, and 0.25), again, where
the discrepancy between the methods is the greatest, that
the scaled common effect assumption is not satisfied in
nearly 50% or more of the simulated data sets at the 0.05
level (sample median p values for test of homogeneity
across 1,000 simulations are 0.059, 0.009, and 0.0008,
respectively). In practice, it is desirable to check the scaled
homogeneity assumption when using the SMAT test.
When this assumption is strongly violated, the M-DF
GEE test is recommended.
Interestingly, in these settings where some phenotypes
are not associated with SNP, the SMAT method with
the exchangeable and independent working correlation
structures tends to be more powerful than SMAT with
an unstructured working correlation structure. However,
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Figure 3. Power for Control þ Affected
Analysis under the Scaled Heterogeneous
Effect Model
Power results for control þ affected anal-
ysis ðn0 ¼ n1 ¼ 700Þ from the scaled het-
erogeneous effect data-generation model
for both the low (left; A, C) and moderate
(right; B, D) disease prevalences and same
(top; A, B) and different (bottom; C, D)
SNP effects for the affected and control in-
dividuals; that is, columns compare power
with low ðp ¼ 0:000745Þ versus moderate
ðp ¼ 0:0745Þ disease prevalences, and,
thus, the effects of the weights, wi, and
rows compare power for disease-indepen-
dent ðað0Þj ¼ að1Þj ; j ¼ 1;.;4Þ versus dis-
ease-dependent ðað0Þj sað1Þj ; j ¼ 1;.;4Þ.
Although the data were generated with
an unstructured correlation matrix, three
working correlation matrix structures for
the joint outcome analyses were consid-
ered: I, independent; E, exchangeable;
and U, unstructured. Power results were
nearly identical with the use of I, E, and
U for the 4-DF GEE tests, whereas power re-
sults were nearly identical with I and E, but
not U, in the 1-DF SMAT; thus, only the re-
sults for GEE (U) and SMAT (E and U) are
included.this is not unexpected. As with traditional GEE analysis,
we would only expect an SMAT analysis with correctly
specified correlation to yield the most efficient estimates
when the mean model itself is correctly specified.
When some phenotypes are not associated with SNP, the
scaled common effect model misspecifies the true mean
model more as the nonzero signal increases, and using
the true correlation matrix (or unstructured working
correlation matrix in this simulation) will not necessarily
yield the most efficient estimates (that is, the smallest
p values).
The plots in the right panel of Figure 4 compare the po-
wer when M0 ¼ M; that is, all phenotypes are associated
with SNP. As expected, SMAT is more powerful than the
other methods.
Simulation: Test for Scaled Homogeneity
The tables and figures for the empirical size and power
results for this set of simulations are included in the
Supplemental Data. Note that only the results of the un-
structured correlation matrix (see Table 1) are included.
Table S1 indicates that the empirical size estimates for
the estimating equation-based score test for homogeneity
are preserved for both the control-only and control þ
affected analyses. Figures S2 and S3 display the power of
the test for homogeneity as a function of (scaled) SNP
effect heterogeneity across outcomes. As expected, as the
SNP effect sizes become more heterogeneous, the power
of the test to detect heterogeneity increases. An SD ofThe Amtrue SNP effect sizes across outcomes of 0.1 yields approx-
imately 80% power to detect heterogeneity at the 0.05
(type I error) level for the given sample size. However, it
is important to note that, even when the scaled effects
are moderately heterogeneous (that is, the null hypothesis
of homogeneous scaled SNP effects may be rejected)
but are in the same direction, the 1-DF scaled common
effect test SMAT remains a powerful test (for example,
see Figure 3).
GWAS on Smoking Behavior Results
Figure 5 displays the log10 p values for SMAT across all
SNPs passing quality control. Manhattan plots for single-
outcome analysis (unadjusted) p values are included in
the Supplemental Data (Figures S4–S7). Quantile-quantile
plots for the SMAT p values as well as the single-outcome
analysis (unadjusted) p values are also included in the Sup-
plemental Data (Figures S8 and S9). There were 13 SNPs
from CDH18 that were nominally significant at p < 103
in at least one outcome. Two of these SNPs,
rs4242066(C) and rs4461636(T) ðR2 > 0:90Þ, had p values
< 105 in two outcomes; both had a negative relationship
with duration and a positive relationship with cessation.
Additionally, these same two SNPs had nominally signifi-
cant p values in the other two outcomes; both had a posi-
tive relationship with initiation ðp < 0:1Þ and a negative
relationship with CPD ðp < 0:001Þ. The direction of the
effects all correspond to less smoking. Similarly for
CACNB2 (chromosome 10, MIM 600003), three SNPs onerican Journal of Human Genetics 92, 744–759, May 2, 2013 753
Figure 4. Power when a Subset of Phenotypes Are Associated with SNP
Power results for control-only analysis ðn0 ¼ 700Þ from the scaled heterogeneous effect model forM ¼ 4 phenotypes (A–C) andM ¼ 10
phenotypes (D–F) for various numbers of a subset of phenotypes associated with SNP ðM0Þ. Three working correlation matrix structures
for the joint outcome analyses were considered: I, independent; E, exchangeable; and U, unstructured. Power results were nearly iden-
tical with the use of I, E, and U for the 4-DF GEE tests, whereas power results were nearly identical with I and E, but not U, in the 1-DF
SMAT; thus, only the results for GEE (U) and SMAT (E and U) are included.this gene were found nominally significant at p < 103 in
at least one outcome, but only one of these SNPs,
rs1277769(C), had p values< 103 in two outcomes (cessa-
tion and CPD). The directional relationships across the
four outcomes and three SNPs were again all consistent
with less smoking. These single-outcome results suggest
that a joint 1-DF SMAT analysis may be advantageous for
at least these SNPs, if not more.
There were 10 SNPs with p values < 105 with the
1-DF SMAT on the basis of the scaled common effect
model, the smallest of which had a p value ¼ 9.5 3
108; the same ten SNPs were identified in both the con-
trol-only and control þ affected analyses (see Table 4). The
p values for the 4-DF GEE test and the min-adj p test for
the same ten SNPs are also provided for comparison. On
the basis of the empirical correlation estimates (see, for
example, Table 1), we chose to report the p values that re-
sulted from using an unstructured working correlation754 The American Journal of Human Genetics 92, 744–759, May 2, 2matrix. However, p values obtained under the indepen-
dent and exchangeable working correlation structures
were of similar magnitudes.
We see several SNPs in Table 4 from CDH18 and one SNP
from CACNB2. Indeed, the five SNPs identified from
CDH18 are highly correlated with correlations in the range
of ½0:69;0:97. Note that the two additional SNPs from
CACNB2 from single-outcome analysis discussed above
had p values < 104 from the 1-DF SMAT and are highly
correlated with the CACNB2 SNP identified in Table 4.
Additionally, SNPs from GEMIN6 (MIM 607006) and
LHPP were also identified. As in the simulations, we see
that the p values from the joint 1-DF SMAT analysis are
smaller than those from the single-outcome-based min-
adjusted p test and the 4-DF GEE test. For the ten SNPs
identified, the p values for the test of homogeneity were
all greater than 0.25, indicating that the common effect
assumption is reasonable.013
Figure 5. Manhattan Plot of Analysis of
Multiple Smoking Behaviors
log10p values from the 1-DF scaled com-
mon effect test SMAT for all SNPs passing
quality control. Analysis was performed
on both affected ðn1 ¼ 696Þ and control
ðn0 ¼ 730Þ ever-smokers with the use of
p ¼ 0:000745 to determine the weights
and an unstructured working correlation
matrix.Moreover, SNPs from CDH18, CACNB2, and LHPP were
identified before in at least one of three previously reported
smoking cessation success clinical trials ðp < 0:01Þ20.
Among the ten SNPs listed in Table 4, there was weak
evidence for SNP 3 gender interaction (unadjusted, indi-
vidual p < 0:05 for CPD) for only the SNPs from CDH18;
stratified by gender, the estimates for SNP effect share
same sign for both genders, but differ in magnitude with
the association stronger for males.Discussion
In this paper, we consider the analysis of multiple contin-
uous secondary phenotypes in case-control studies.
When multiple phenotypes measure the same underlying
trait in the same direction (after transformation), we pro-
pose a powerful test, SMAT, for the common effect of a
given SNP on multiple phenotypes using the scaled mar-
ginal model14 and use inverse probability-weighted esti-
mating equations to adequately account for potential
ascertainment bias induced by case-control sampling.
This approach is robust to whether or not the secondary
phenotypes are related to a primary disease outcome. In
both simulation and data analyses, we demonstrate
that, when the scaled effects of multiple phenotypes are
homogeneous or moderately heterogeneous, the pro-
posed 1-DF SMAT based on the scaled common effect
model is more powerful than both the more traditional
multivariate M-DF GEE test and the test with the single-
outcome-based minimum p value adjusted for multiple
comparisons.
Our approach allows one to account for arbitrary correla-
tion among phenotypes and is also robust to the misspeci-
fication of the correlation among multiple phenotypes
with the sandwich method. More power can be gainedThe American Journal of Humaby correctly specifying the correlation
among multiple phenotypes.
When multiple phenotypes mea-
sure the same underlying trait in the
same biological direction (after trans-
formations), one would expect that
they are positively correlated. In this
situation, the proposed that 1-DF
SMAT is powerful for analyzingmulti-
ple (secondary) phenotypes in a rangeof scenarios when the scaled effects of multiple pheno-
types are homogeneous or moderately heterogeneous. Spe-
cifically, the 1-DF SMAT is derived under the scaled com-
mon effect model. As expected, it is most powerful when
the scaled common effect model holds. Furthermore, our
results show that, when the scaled SNP effects on multiple
outcomes are moderately heterogeneous, the 1-DF SMAT
based on the scaled common effect model remains to
have the correct size and a higher power than themultivar-
iate M-DF test, assuming moderate heterogeneous SNP
effects. In GWASs, given that the SNP effects are often
small or moderate, it is reasonable to assume homoge-
neous or moderately heterogeneous SNP effects for scaled
multiple continuous phenotypes, provided they measure
the same underlying trait in the same direction (after trans-
formation). This approach allows one to borrow informa-
tion across multiple correlated phenotypes to increase
test power, especially when SNP effects are weak, as in
GWASs. Also, we proposed a scaled homogeneity test to
assess the assumption of scaled homogeneous SNP
effects. When a good portion of multiple phenotypes are
not associated with SNP, the scaled homogeneity assump-
tion (which can be tested with the scaled homogeneity
test) is likely to be strongly violated, and the SMATmethod
might be less powerful; in these situations, the M-DF GEE
test or individual phenotype analysis is recommended.
The proposed method can be also applied to studying
pleiotropic effects. When modeling pleiotropic associa-
tions, in which loci are simultaneously associated with
multiple phenotypes, to apply SMAT, it is desirable to first
consider examining whether the multiple phenotypes bio-
logically measure the same underlying trait or disease pro-
cess in the same direction (after transformation); that is, if
they are positively correlated after transformation. If not,
or if they measure different underlying traits in different
directions, or if a good proportion of phenotypes mightn Genetics 92, 744–759, May 2, 2013 755
Table 4. Top Ten SNPs
Control-Only Control þ Affected
SNP MAF Chr. Gene SMAT (1-DF) min-adj p GEE (4-DF) SMAT (1-DF) min-adj p GEE (4-DF)
rs1056104 0.082 2 GEMIN6 5.75 3 106 1.6 3 103 4.04 3 104 5.74 3 106 1.69 3 103 4.08 3 104
rs6847801 0.073 4 N/A 9.72 3 107 1.65 3 103 4.18 3 106 9.81 3 107 1.66 3 103 4.23 3 106
rs6451476 0.095 5 CDH18 9.45 3 106 2.95 3 103 4.48 3 104 9.43 3 106 2.94 3 103 4.48 3 104
rs4242066 0.090 5 CDH18 9.50 3108 8.61 3 107 2.76 3 107 9.53 3 108 8.53 3 107 2.77 3 107
rs1391429 0.098 5 CDH18 9.43 3 107 2.59 3 104 1.97 3 105 9.44 3 107 2.57 3 104 1.98 3 105
rs4461636 0.093 5 CDH18 1.41 3107 2.47 3 105 1.78 3 106 1.41 3 107 2.46 3 105 1.79 3 106
rs4866159 0.101 5 CDH18 1.11 3 106 5.1 3 104 2.76 3 105 1.11 3 106 5.12 3 104 2.77 3 105
rs1277769 0.112 10 CACNB2 6.79 3106 7.70 3 104 2.57 3 104 6.82 3 106 7.66 3 104 2.58 3 104
rs17152064 0.054 10 LHPP 7.53 3 106 3.16 3 103 6.41 3 105 7.36 3 106 3.14 3 103 6.32 3 105
rs10902443 0.127 12 N/A 9.27 3 106 9.76 3 103 6.36 3 104 9.29 3 106 9.73 3 103 6.44 3 104
Top SNPs from the GWAS scan with a 1-DF scaled common effect test SMAT for control-only (left) and control þ affected (right) on the four square-root-trans-
formed smoking behavior outcomes. Adjusted p values from single outcome and unadjusted p values from the 4-DF GEE tests are also listed for comparison; joint
outcome analysis p values reported using unstructured correlation matrix (n0 ¼ 730, n1 ¼ 696; p ¼ 0:000745).not be associated with SNP, it is desirable to use the M-DF
GEE test assuming heterogeneous SNP effects or simply
analyze each phenotype separately for the improvement
of power. To check this, one can simply calculate the sam-
ple correlation of multiple phenotypes or use biological
knowledge. One can also perform the proposed scaled ho-
mogeneity test. In fact, for these scenarios, it might not be
desirable to analyze multiple phenotypes simultaneously,
because the results from the joint analysis might not be
easily interpretable. Furthermore, when a large number
of phenotypes are analyzed simultaneously, and if the ma-
jority of the phenotypes are not associated with a SNP, a
multivariate M-DF GEE test could lose power compared
to analyzing each phenotype separately.
In this paper, we focus on using the IPW method for
analyzing multiple secondary phenotypes to correct for
ascertainment bias in case-control studies where appro-
priate weights,wi, determined on the basis of disease preva-
lence, are used. This approach is easy to implement and
robust to the distributions of phenotypes. An alternative
approach is to extend the retrospective likelihood
methods12 for multiple secondary phenotypes. Although
this approach could potentially be more powerful than the
proposed IPW approach, it is more complex and computa-
tionally intensive and is likely to be less robust in compari-
son to theproposed IPWmethod, given that a full likelihood
and correct specification of the correlation among pheno-
types is required. However, additional research is needed.
Weappliedourproposedmethods to investigate SNPasso-
ciations with multiple secondary smoking phenotypes and
identified several SNPs of biological interest. Future research
is needed to validate these findings. Recent large-scale
GWASs (obtained by pooling data through meta analyses)
and candidate gene studies for smoking behavior and nico-
tine dependence have identified several plausible genetic
variants, an area onChr15q24-25.1 beingmost consistently756 The American Journal of Human Genetics 92, 744–759, May 2, 2identified.21–29 However, the effects identified in these pub-
lished analyses were quite small and not detectable in the
present analysis, most likely because of the limited sample
size in our study (approximately 700 affected individuals
and 700 control individuals).
The proposed method can be extended in a number of
ways. Although themodels considered in this work assume
a common set of covariates, xi, for each outcome, the
models can easily be modified to handle different sets of
covariates for each outcome. We can also consider extend-
ing the model to handle multiple SNPs in a region; e.g., a
gene, to potentially further improve power. Finally, it is
also of interest to develop a similar framework for mixed
outcome types (e.g., continuous and binary outcomes) if
they measure the same underlying trait.Appendix A: Unbiased Estimating Equations
In order to see that the estimating Equations 5 and 6 are
indeed unbiased, let ISðiÞ be an indicator of individual i
being sampled in a case-control data set from a cohort of
size N. Clearly, ISðiÞ ¼ 1 for all n ¼ n0 þ n1 individuals in
the case-control sample and 0 otherwise. The expectation
of Equation 5 is given by
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The first equality follows from the definition of ISðiÞ and
the law of iterated expectation. The penultimate equality
results from the fact that EfISwijDi;yi;Xig ¼
EfISwijDig ¼ n=N. This is because EðISðiÞ ¼ 1jDiÞ ¼
PrðISðiÞ ¼ 1jDiÞ, where PrðISðiÞ ¼ 1jDiÞ is the conditional
probability of individual i within the cohort being
sampled, given disease status. Note that PrðISðiÞ ¼
1jDi ¼ 1Þ ¼ n1=ðNpÞ ¼ ðn=NÞð1=wiÞ and PrðISðiÞ ¼ 1jDi ¼
0Þ ¼ n0=ðNð1 pÞÞ ¼ ðn=NÞð1=wiÞ for weight, wi, defined
in Equation 7. In other words, the weight, wi, apart from
a constant factor, is the inverse probability of individual i
being sampled in the case-control sample. The final
equality brings us to the cohort-based unbiased estimating
equation of Roy et al.14
For Equation 6, denote ½Xigj ¼ xTi bj þ sia for each j.
Similarly, for each j ¼ 1;.;M,
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Following similar arguments above, the final equality
again brings us to the cohort-based unbiased estimating
equation of Roy et al.14Appendix B: Parameter Estimates and Their
Standard Errors
After setting initial values for s2 and R; we estimate g as
gnew ¼
 Xn
i¼1
wiX
T
i R
1Xi
!1Xn
i¼1
wiX
T
i R
1yi :
Given the current estimate of g; we update the estimate
of s2 using the Newton-Raphson (NR) method. Conve-
niently, terms required for the NR algorithm are also neces-
sary for computation of the sandwich formula (see below
for details) for the standard errors. Specifically, we have
s2new ¼ s2old þ
"Xn
i¼1
wi

J1þ 1
2
diagðXigÞJ1diagðXigÞ
#1
3
(Xn
i¼1
wi

J1=2diag

yi
ðyi XigÞ  1M
)
;
whereJ ¼ diagðs2oldÞ. The above updates are repeated until
convergence.
For the estimation of the standard error of the parame-
ters, denote the estimating equation of interest byThe AmUðdÞ ¼Pni¼1UiðdÞ ¼ 0, where d ¼ ðs2T ;gTÞ and Ui ¼
ðUT1i;UT2iÞT . Here, U1i and U2i correspond to the
summands of Equations 6 and 5, respectively. Let bd be
the solution of UðdÞ ¼ 0: The variance of estimator bd
can be estimated as I1, where I ¼ HðbdÞTfPni¼1UiðbdÞ
UiðbdÞTg1HðbdÞ and
HðdÞ ¼ E
vUðdÞ
vdT

¼

H11 H12
H21 H22

;
with
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Appendix C: Score Test for the Assumption
of Scaled Common Effect
Let g0 ¼ ðbT1 ;.;bTM ; h1ÞT ; d0 ¼ ðs2T ;g0TÞT ; and
h ¼ ðh1;.; hMÞT and partition the estimating functions
as UðdÞ ¼ ðU1T ;U2T ÞT , where
U1 ¼
0@Pi win1J1=2diagyiðyi Xig0  siD1hÞ  1MP
i
wiX
T
i R
1ðyi Xig0  siD1hÞ
1A
(Equation C1)
U2 ¼
X
i
wisiLR
1yi Xig0  siD1h; (Equation C2)
where Dj is the M3M identity matrix with the j
th diagonal
element replaced by 0, and L is an ðM  1Þ3M matrix
which is the identity matrix with the first row deleted.
Note that Equation C1 is the estimating function for d0,
and U2 is the estimating function for h2;.; hM :Using the
results of Breslow30, the score statistic
S ¼
n
U2
bd0ToTcov1nU2bd0oU2bd0T
can be obtained easily, given that the computation of
covfU2ðbd0Þg is a straightforward extension of the formulae
in Roy et al.14 by accommodating the weights. Under the
null hypothesis of common effect, the statistic, S, asymp-
totically follows a c2 distribution with M  1 degrees of
freedom.Supplemental Data
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